Low‐grade oncocytic tumour of the kidney is characterised by genetic alterations of <i>TSC1</i>, <i>TSC2</i>, <i>MTOR</i> or <i>PIK3CA</i> and consistent <scp>GATA3</scp> positivity
Sean R. Williamson(Cleveland Clinic), Sambit K. Mohanty(Government of Haryana), Mahmut Akgül(Albany Medical Center Hospital), Pilar Fraile Gómez(Universidad de Salamanca), Joanna Rogala(Łukasiewicz Research Network – PORT Polish Center for Technology Development), Stela Bulimbašić(University Hospital Centre Zagreb), Muhammad T. Idrees(Indiana University School of Medicine), Ondřej Hes(Charles University), Sourav Mishra(Advanced Medical Research Institute), Jesse K. McKenney(Cleveland Clinic), Nakul Y Sampat(Advanced Medical Research Institute), Éva Compérat(Vienna General Hospital), Ankur R. Sangoi(El Camino Hospital), Sudha M. Sadasivan(Henry Ford Health System), Daniel M. Berney(Queen Mary University of London), Abhishek Satapathy(Advanced Medical Research Institute), Albert M. Levin(Henry Ford Hospital), Liang Cheng(Brown University), Shivani Sharma(Government of Haryana), Aditi Aggarwal(Government of Haryana), Shilpy Jha(Advanced Medical Research Institute), Kiril Trpkov(University of Calgary)
Cited by 47
Related Papers
The Banff 97 working classification of renal allograft pathology
|Kidney International|1999|3.1k
Antibody-Mediated Rejection Criteria - an Addition to the Banff ’97 Classification of Renal Allograft Rejection
|American Journal of Transplantation|2003|1.1k
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|618
EAU Guidelines on Penile Cancer: 2014 Update
|European Urology|2014|594